Literature DB >> 19049831

Long-term follow-up of patients with nonalcoholic fatty liver.

Nila Rafiq1, Chunhong Bai, Yun Fang, Manirath Srishord, Arthur McCullough, Terry Gramlich, Zobair M Younossi.   

Abstract

BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of conditions ranging from simple hepatic steatosis to nonalcoholic steatohepatitis (NASH) convincingly. NASH is the only subtype of NAFLD that has been shown to progress relatively, although these findings were reported from studies with short follow-up periods. We assessed the long-term outcomes of a NAFLD cohort.
METHODS: Patients with NAFLD established by biopsy were identified in databases and categorized as NASH or non-NASH. Mortality data and causes of death were obtained from National Death Index Plus. The nonparametric Kaplan-Meier method with log-rank test and multivariate analyses with a Cox proportional hazard model were used to compare different NAFLD subtypes and to identify independent predictors of overall and liver-related mortality.
RESULTS: Of 173 NAFLD patients (age at biopsy, 50.2 +/- 14.5 y; 39.9% male; 80.8% Caucasian; 28.9% with type II diabetes), 72 (41.6%) had NASH and 101 (58.4%) had non-NASH NAFLD. Over the follow-up period, the most common causes of death were coronary artery disease, malignancy, and liver-related death. Although overall mortality did not differ between the NAFLD subtypes, liver-related mortality was higher in patients with NASH (P < .05). Independent predictors of liver-related mortality included histologic NASH, type II diabetes, older age at biopsy, lower albumin levels, and increased levels of alkaline phosphatase (P < .05).
CONCLUSIONS: This long-term follow-up evaluation of NAFLD patients confirms that NASH patients have increased liver-related mortality compared with non-NASH patients. In addition, patients with NAFLD and type II diabetes are especially at risk for liver-related mortality.

Entities:  

Mesh:

Year:  2008        PMID: 19049831     DOI: 10.1016/j.cgh.2008.11.005

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  232 in total

1.  A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis.

Authors:  Zobair M Younossi; Sandra Page; Nila Rafiq; Aybike Birerdinc; Maria Stepanova; Noreen Hossain; Arian Afendy; Zahra Younoszai; Zachary Goodman; Ancha Baranova
Journal:  Obes Surg       Date:  2011-04       Impact factor: 4.129

2.  Hepatic gene expression of Caucasian and African-American patients with obesity-related non-alcoholic fatty liver disease.

Authors:  Maria Stepanova; Noreen Hossain; Arian Afendy; Kellie Perry; Zachary D Goodman; Ancha Baranova; Zobair Younossi
Journal:  Obes Surg       Date:  2010-01-30       Impact factor: 4.129

Review 3.  Histopathology of nonalcoholic fatty liver disease.

Authors:  Elizabeth M Brunt; Dina G Tiniakos
Journal:  World J Gastroenterol       Date:  2010-11-14       Impact factor: 5.742

Review 4.  Fructose-mediated effects on gene expression and epigenetic mechanisms associated with NAFLD pathogenesis.

Authors:  Johanna K DiStefano
Journal:  Cell Mol Life Sci       Date:  2020-06       Impact factor: 9.261

5.  Serum γ-glutamyltranspeptidase predicts all-cause, cardiovascular and liver mortality in older adults.

Authors:  Rohit Loomba; Iliana Doycheva; Ricki Bettencourt; Benjamin Cohen; Christina L Wassel; David Brenner; Elizabeth Barrett-Connor
Journal:  J Clin Exp Hepatol       Date:  2013-03-01

Review 6.  Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease.

Authors:  Stefano Ballestri; Amedeo Lonardo; Stefano Bonapace; Christopher D Byrne; Paola Loria; Giovanni Targher
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

7.  Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.

Authors:  Shira Zelber-Sagi; Muriel Webb; Nimer Assy; Laurie Blendis; Hanny Yeshua; Moshe Leshno; Vlad Ratziu; Zamir Halpern; Ran Oren; Erwin Santo
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

Review 8.  Nonalcoholic fatty liver disease: current issues and novel treatment approaches.

Authors:  Romina Lomonaco; Nishanth E Sunny; Fernando Bril; Kenneth Cusi
Journal:  Drugs       Date:  2013-01       Impact factor: 9.546

9.  Non-alcoholic fatty liver disease-associated hepatocellular carcinoma: effect of hepatic steatosis on major hepatocellular carcinoma features at MRI.

Authors:  Scott M Thompson; Ishan Garg; Eric C Ehman; Shannon P Sheedy; Candice A Bookwalter; Rickey E Carter; Lewis R Roberts; Sudhakar K Venkatesh
Journal:  Br J Radiol       Date:  2018-08-29       Impact factor: 3.039

10.  Risk factors for hepatocellular carcinoma (HCC) in the northeast of the United States: results of a case-control study.

Authors:  Yi Shen; Harvey Risch; Lingeng Lu; Xiaomei Ma; Melinda L Irwin; Joseph K Lim; Tamar Taddei; Karen Pawlish; Antoinette Stroup; Robert Brown; Zhanwei Wang; Wei Jia; Linda Wong; Susan T Mayne; Herbert Yu
Journal:  Cancer Causes Control       Date:  2020-02-14       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.